Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression

Key Points Progression of AML is associated with pro-inflammatory mediators through altered expression levels of CR1, DPEP1, IL1R1, and ST18. Upregulated CD6 and downregulated INSR are nodes in gene expression networks linked to AML relapse, according to machine learning analysis.

[1]  Steven J. M. Jones,et al.  A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia , 2021, Nature Communications.

[2]  Y. Pawitan,et al.  The transcriptome‐wide landscape of molecular subtype‐specific mRNA expression profiles in acute myeloid leukemia , 2021, American journal of hematology.

[3]  J. Komorowski,et al.  Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets. , 2021, Blood advances.

[4]  Guoji Guo,et al.  A single-cell survey of cellular hierarchy in acute myeloid leukemia , 2020, Journal of Hematology & Oncology.

[5]  Jiamin Zhang,et al.  DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia , 2020, British journal of haematology.

[6]  Xiaoming Wang,et al.  Interleukin-1β inhibits normal hematopoietic expansion and promotes acute myeloid leukemia progression via the bone marrow niche. , 2020, Cytotherapy.

[7]  E. Yoon,et al.  NFATC4 Promotes Quiescence and Chemotherapy Resistance in Ovarian Cancer , 2019, bioRxiv.

[8]  M. Creyghton,et al.  AML Subtype Is a Major Determinant of the Association between Prognostic Gene Expression Signatures and Their Clinical Significance. , 2019, Cell reports.

[9]  M. Ratajczak,et al.  The Complement Cascade as a Mediator of Human Malignant Hematopoietic Cell Trafficking , 2019, Front. Immunol..

[10]  Jan Komorowski,et al.  R.ROSETTA: an interpretable machine learning framework , 2019, BMC Bioinformatics.

[11]  M. Gottesman,et al.  Heterogeneity in refractory acute myeloid leukemia , 2019, Proceedings of the National Academy of Sciences.

[12]  P. May,et al.  Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. , 2019, Cancer research.

[13]  Toshiki Terao,et al.  Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment , 2019, Cells.

[14]  G. Tonon,et al.  Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation , 2019, Nature Medicine.

[15]  G. Pinkus,et al.  Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity , 2019, Cell.

[16]  M. Heuser,et al.  Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome , 2018, Leukemia.

[17]  R. Collins,et al.  Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.

[18]  Hamid Bolouri,et al.  The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions , 2017, Nature Medicine.

[19]  C. Bloomfield,et al.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.

[20]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[21]  K. Jahnukainen,et al.  Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia , 2017, British journal of haematology.

[22]  R. Collins,et al.  Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. , 2017, Cell reports.

[23]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[24]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[25]  L. Marchionni,et al.  Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia , 2015, Science Translational Medicine.

[26]  M. D. Den Boer,et al.  Gene Expression Profiles Associated with Pediatric Relapsed AML , 2015, PloS one.

[27]  Richard A. Moore,et al.  GLI2 inhibition abrogates human leukemia stem cell dormancy , 2015, Journal of Translational Medicine.

[28]  K. Wagner,et al.  Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects , 2015, Clinical Cancer Research.

[29]  S. Devine,et al.  Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  D. Reinhardt,et al.  Prospective Validation of a New Method of Monitoring Minimal Residual Disease in Childhood Acute Myelogenous Leukemia , 2014, Clinical Cancer Research.

[31]  Markus Hsi-Yang Fritz,et al.  CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia , 2014, Journal of Hematology & Oncology.

[32]  H. Hackl,et al.  A gene expression profile associated with relapse of cytogenetically normal acute myeloid leukemia is enriched for leukemia stem cell genes , 2014, Leukemia & lymphoma.

[33]  Ozlem Keskin,et al.  The Structural Pathway of Interleukin 1 (IL-1) Initiated Signaling Reveals Mechanisms of Oncogenic Mutations and SNPs in Inflammation and Cancer , 2014, PLoS Comput. Biol..

[34]  B. Sipos,et al.  Dipeptidase 1 (DPEP1) is a marker for the transition from low-grade to high-grade intraepithelial neoplasia and an adverse prognostic factor in colorectal cancer , 2013, British Journal of Cancer.

[35]  Hui Zhou,et al.  The microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR pathway proteins , 2013, Experimental and therapeutic medicine.

[36]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[37]  Jochen Gaedcke,et al.  DPEP1 Inhibits Tumor Cell Invasiveness, Enhances Chemosensitivity and Predicts Clinical Outcome in Pancreatic Ductal Adenocarcinoma , 2012, PloS one.

[38]  Sherine F. Elsawa,et al.  GLI2 Transcription Factor Mediates Cytokine Cross-talk in the Tumor Microenvironment* , 2011, The Journal of Biological Chemistry.

[39]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[40]  Y. Toiyama,et al.  DPEP1, expressed in the early stages of colon carcinogenesis, affects cancer cell invasiveness , 2011, Journal of Gastroenterology.

[41]  K. Jahnukainen,et al.  Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  T. MacDonald,et al.  Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. , 2011, The Journal of clinical investigation.

[43]  L. Boscá,et al.  Cilastatin Attenuates Cisplatin-Induced Proximal Tubular Cell Damage , 2010, Journal of Pharmacology and Experimental Therapeutics.

[44]  H. Kantarjian,et al.  Late relapses in acute myeloid leukemia: analysis of characteristics and outcome , 2010, Leukemia & lymphoma.

[45]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[46]  Israel Steinfeld,et al.  BMC Bioinformatics BioMed Central , 2008 .

[47]  D. Graves,et al.  The transcription factor ST18 regulates proapoptotic and proinflammatory gene expression in fibroblasts , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  A. Peixoto,et al.  Extracellular Isoforms of CD6 Generated by Alternative Splicing Regulate Targeting of CD6 to the Immunological Synapse1 , 2007, The Journal of Immunology.

[49]  Zohar Yakhini,et al.  Discovering Motifs in Ranked Lists of DNA Sequences , 2007, PLoS Comput. Biol..

[50]  R. Siebert,et al.  ST18 is a breast cancer tumor suppressor gene at human chromosome 8q11.2 , 2004, Oncogene.

[51]  B. Haynes,et al.  Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand , 1995, The Journal of experimental medicine.

[52]  F. Lanza,et al.  Complement receptor 1 (CR1) expression in chronic myeloid leukemia. , 1992, Leukemia & lymphoma.

[53]  D. Fearon,et al.  Expression of C3b receptors on human be cells and myelomonocytic cells but not natural killer cells. , 1983, Journal of immunology.

[54]  V. Nussenzweig,et al.  Functional properties of membrane-associated complement receptor CR1. , 1983, Journal of immunology.

[55]  D. Fearon.  Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte , 1980, The Journal of experimental medicine.

[56]  C. Lederer,et al.  A novel family of katanin-like 2 protein isoforms (KATNAL2), interacting with nucleotide-binding proteins Nubp1 and Nubp2, are key regulators of different MT-based processes in mammalian cells , 2015, Cellular and Molecular Life Sciences.

[57]  Tannishtha Reya,et al.  Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia , 2009, Nature.

[58]  Jan Komorowski,et al.  BIOINFORMATICS ORIGINAL PAPER doi:10.1093/bioinformatics/btm486 Data and text mining Monte Carlo , 2022 .